Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5179794
Max Phase: Preclinical
Molecular Formula: C56H95FN22O10
Molecular Weight: 1255.52
Associated Items:
ID: ALA5179794
Max Phase: Preclinical
Molecular Formula: C56H95FN22O10
Molecular Weight: 1255.52
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)CCC(=O)N[C@@H](CCCCNC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCCCC(=O)N1CCN(c2ncnc3[nH]ccc23)CC1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(N)=O)C(=O)NCC(=O)CF
Standard InChI: InChI=1S/C56H95FN22O10/c1-3-35(2)46(53(89)70-33-36(80)32-57)77-44(83)21-20-43(82)74-40(51(87)76-41(17-13-26-69-56(63)64)52(88)75-38(47(58)85)15-11-24-67-54(59)60)14-9-10-23-66-50(86)39(16-12-25-68-55(61)62)73-42(81)18-7-5-4-6-8-19-45(84)78-28-30-79(31-29-78)49-37-22-27-65-48(37)71-34-72-49/h22,27,34-35,38-41,46H,3-21,23-26,28-33H2,1-2H3,(H2,58,85)(H,66,86)(H,70,89)(H,73,81)(H,74,82)(H,75,88)(H,76,87)(H,77,83)(H4,59,60,67)(H4,61,62,68)(H4,63,64,69)(H,65,71,72)/t35-,38+,39+,40-,41+,46-/m0/s1
Standard InChI Key: WYHDFSAXUNSCJZ-WDMGAOPMSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1255.52 | Molecular Weight (Monoisotopic): 1254.7586 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Sõrmus T, Lavogina D, Teearu A, Enkvist E, Uri A, Viht K.. (2022) Construction of Covalent Bisubstrate Inhibitor of Protein Kinase Reacting with Cysteine Residue at Substrate-Binding Site., 65 (16.0): [PMID:35960538] [10.1021/acs.jmedchem.2c00067] |
Source(1):